Adults with newly diagnosed high-risk endometrial cancer invited to be in a research study testing an immunotherapy drug.

UVA Tracking #
Principal Investigator
Linda R Duska
Sheena Clift
Contact Phone
Official Trial Title
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have newly diagnosed high-risk endometrial cancer. This trial will compare pembrolizumab given with chemotherapy (with or without radiation therapy) to placebo given with chemotherapy (with or without radiation therapy). The chemotherapy combination of carboplatin and paclitaxel is a standard treatment for women with your type of endometrial cancer.

The treatment period is estimated to last approximately 12 months. The subsequent follow-up period will involve a visit about every 6 months (until 2 years after starting treatment) and every 1 year after that

Travel Reimbursement: $50 per completed visit

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here: